Your mission is to apply your deep expertise in in vivo pharmacology to drive the preclinical evaluation of our innovative Bicycle® Radio Conjugates (BRCs).
Independently execute and interpret key preclinical studies to generate critical data needed to understand their activity, guide their optimization, and support the advancement of our next-generation cancer therapies.
Design, execution, and interpretation of in vivo pharmacology studies to evaluate the biodistribution, mechanism of action, and PK/PD/efficacy relationships of our BRCs.
Manage the execution of in vivo studies through a network of CROs and academic collaborators, ensuring timely delivery of high-quality data.
Act as a key technical expert on cross-functional project teams, collaborating with chemistry, biology, DMPK, and toxicology experts to contribute to project goals.
Contribute to the identification and validation of pharmacodynamic biomarkers to support preclinical and clinical development.
Perform hands-on in vivo experimental work as required to support project progression and ensure timely data delivery.
Effectively document and communicate complex study results and their interpretation to project teams and in broader scientific forums.
Contribute to publications for peer-reviewed journals and present data at scientific conferences.
Act as a source of technical expertise for the team, sharing best practices in in vivo techniques and radiopharmaceutical handling.

Strong experience in in vivo pharmacology and tumour biology, gained in a biopharmaceutical or academic setting.
Essential hands-on experience in preclinical radiopharmaceutical assessment, including PET/SPECT imaging and ex vivo biodistribution analysis.
Experience working with external CROs or academic collaborators to execute studies.
Experience with radionuclide
or toxin-conjugates (e.g., radiopharmaceuticals, ADCs) and a background in cancer biology is required.
Excellent attention to detail and strong organizational and communication skills.
Knowledge of radiochemistry, radiolabelling, or dosimetry would be an advantage.
A current Home Office Personal License (PIL) is highly desirable

State-of-the-art campus environment with on campus restaurant and Montessori nursery
Flexible working environment
Competitive reward including annual company bonus
Employee recognition schemes
28 days annual leave in addition to bank holidays + option to buy up to 5 additional days annually
Employer contribution to pension (employee does not have to contribute)
Life assurance cover 4x basic salary
Private Medical Insurance, including optical and dental cover
Enhanced parental leave policies
Group income protection
Employee assistance program
Health Cash Plan
Access to company subsidized gym membership
Eligibility for an option grant to subscribe to shares in Bicycle Therapeutics plc.
Cycle to work scheme

Senior Scientist, In Vivo Pharmacology – Radiopharmaceuticals

Key skills